Sleep disturbances are among the most frequent and disruptive symptoms associated with menopause which can impact women’s health and quality of life
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
EBITDA before special items falls 1.3 percent to € 4.41 billion
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
Acquisition of exclusive commercialization rights for European markets
An accomplished R&D leader and champion of the application of AI to drug discovery
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Subscribe To Our Newsletter & Stay Updated
